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Abstract
Patient satisfaction, assessed using the IOQ, is high after retropubic and transobturator slings. In our
collective, relapse incontinence is higher after TOT.
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Objective: The aim of the Incontinence Outcome Questionnaire (IOQ) is to assess quality of life and 
patient-reported outcome after midurethral slings. 
Methods: In this retrospective study, 626 patients with a minimum follow-up period of one year were 
sent the IOQ. 422/626 (67.4%) patient responses were evaluated. 
Results: The mean IOQ QoL extended score was 33.7±17.5 and comparable for TVT, TOT and TVT-
O. Evaluation of IOQ question about re-admission revealed a total of 32 patients (18 TVT, 12 TOT and 
2 TVT-O) who underwent a subsequent operation due to sling related complications. Freedom from 
re-operation for recurrent SUI at 1, 2, and 5 years was 100%, 99.7±0.3% and 99.7±0.3% for TVT, 
100% for TVT-O, and 94.2±2.5%, 91.9±2.9%, and 89.9±3.5% for TOT, respectively (p<0.001). 
Conclusions: Patient satisfaction, assessed using the IOQ, is high after retropubic and transobturator 
slings. In our collective, relapse incontinence is higher after TOT. 
 
 
 
 
Keywords: Incontinence Outcome Questionnaire (IOQ), patient satisfaction, TOT, TVT, TVT-O, stress 
urinary incontinence (SUI) 
 
 
Brief summary: Patient satisfaction, assessed using the IOQ, is high after retropubic and 
transobturator slings. In our collective, relapse incontinence is higher after TOT. 
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Introduction 
Urinary incontinence, defined as any involuntary loss of urine, has a negative impact on the social, 
physical and psychological life of women affected [1,2]. The current evidence base for the surgical 
treatment of stress urinary incontinence (SUI) suggests that the insertion of a midurethral tape will 
become the treatment of choice [3]. For the retropubic route – first introduced as tension-free vaginal 
tape (TVT) by Ulmsten and Petros in 1995 – long-term results of up to 11 years are well documented 
and continence rates of 90 % are reported [4,7]. In 2001 Delorme introduced a transoburator tape 
outside-in TOT [5] and in 2003 de Leval introduced the inside-out TVT-O [6]. Subsequent publications 
for transobturator slings cover only short- to mid-term follow-up of a maximum of 3 years [8]. Overall, 
all tapes establish continence effectively and can be considered as safe and durable surgical 
procedures for SUI [7,8].  
Operations for urinary incontinence seldom lead to severe morbidity and the primary impact is on 
improved quality of life (QoL) and patient satisfaction. The ICS standardization committee emphasizes 
the importance of postoperative survey on subjective outcome, patient satisfaction and health-related 
quality of life parameters measured by specific questionnaires [9]. In the 4th edition of the International 
Consultation on Incontinence, self-completed patient questionnaires are considered to represent the 
best clinical review of symptom impact and treatment benefit. QoL after slings procedures was the 
objective of several trials using different incontinence specific questionnaires like the Urogenital 
Distress Inventory (UDI-6) [10], Incontinence Impact Questionnaire (IIQ-7) [7,11,12], Incontinence 
Severity Index (ISI), Pelvic Floor Distress Inventory, Short Form-20 (PFI-20), Pelvic Floor Impact 
Questionnaire, Short Form-7 (PFIQ-7) and the Pelvic Organ Prolapse/Urinary Incontinence Sexual 
Questionnaire, Short Form (PISQ-12) [13]. Significant improvements of QoL after sling procedures 
have been shown for retropubic and transobturator slings and are persistent for up to 11 years. In 
order to evaluate QoL and postoperative patient satisfaction without preoperative baseline data, a 
specific one-point measurement instrument is needed. Therefore, a detailed 27-item Incontinence 
Outcome Questionnaire (IOQ), validated for the German language, was constructed to assess patient-
reported outcome and QoL after insertion of a midurethral tape [14]. The IOQ is considered as a valid 
and reliable instrument when baseline or preoperative data is unavailable because of the partial 
correlation with objective clinical parameters such as continence. Our study was designed to answer 
the following primary question: How is the patient satisfaction one year or more after midurethral sling 
procedure using the IOQ? Secondary questions were the applicability of the IOQ one year and more 
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after operation and differences in outcome parameters among different sling types.
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Material and Methods 
Patient and pre-operative evaluation 
In this retrospective study, 626 women who underwent midurethral sling surgery at two medical 
centers (one university hospital and one district hospital) between January 1999 and December 2007 
were identified as follows using a computerized medical record system: 452 (72.2 %) TVT, 119 (19.0 
%) TOT (Monarc), 36 (5.8 %) TVT-O, 9 (1.4 %) intravaginal sling (IVS), and 10 (1.6 %) readjustable 
sling system (Remeex). The minimal follow-up after operation was determined as one year. All 
patients were evaluated preoperatively by means of a patient history, gynecological examination with 
a positive cough test and urine control (dipstick) to exclude a urinary tract infection. All subjects had a 
clinical SUI. The inserted TVT and TVT-O were manufactured by Ethicon, Neuchâtel, Switzerland and 
distributed by Gynecare Switzerland; the TOT Monarc® was manufactured by American Medical 
Systems, Minnetonka USA and distributed by Promedics Switzerland. Ten surgeons, trained in 
urogynaecological surgery, performed the operations according to the original methods. Every 
surgeon was carrying out all three sling procedures. The anesthesia was usually local anesthesia or 
dependent on concomitant surgery.  
Ethical approval was obtained from the ethics committees of Zurich University Hospital and Altdorf 
District Hospital, Canton Uri. This clinical trial has been registered at http://www.clinicaltrials.gov, and 
the identification number is NCT01042275. 
 
Outcome measures 
All patients identified were sent the IOQ, consisting of 27 questions, by mail. Patients who did not 
respond to the first mailing, received a second mail. The IOQ consists of 27 questions comprised as 
follows: four related to symptoms (pain, postoperative symptoms, preoperative OAB, change in OAB 
symptoms pre- or postoperatively), four about complications (urinary or other infection, hospital 
readmission, residual urine), seven about QoL (felt tired/drained/lacking energy, felt irritable/snappy, 
felt depressed/tearful, general evaluation of health, limitations in daily activities, change in sexual 
activity, change in body perception), five about satisfaction (changes of symptoms  pre- and 
postoperatively, time of recovery, satisfaction with information, improvement in well being, 
recommending the operation), one about problems with urinary incontinence before surgery, and six 
address demographic and treatment-related information (age, occupation, living arrangements, reason 
for operation, hormone replacement therapy, and time interval to operation). Each item is rated onto a 
0-100 scale (0 = minimum, 100 = maximum impairment), from which two scores are calculated: one 
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for the 7 QoL and the 5 satisfaction questions, and an extended score which includes additional 
questions about postoperative symptoms, post-void residual urine volume and change in OAB 
symptoms as well. A visual analogue scale was added (VAS, where 0 means no urinary problems and 
10 means unbearable urinary problems) to assess the subjective grade of discomfort for urine loss 
pre- and postoperatively [30].  Further analysis of the answers related to re-admission (IOQ4) was 
carried out by cross-checking patient answers and remarks with our clinical information system. 
 
Statistics 
All patients who completed the questionnaire following TVT, TOT Monarc or TVT-O procedure were 
included for statistical analysis. Statistic evaluation was carried out with the Kruskal-Wallis, chi-square 
or Fisher’s exact test as appropriate, using Intercooled Stata 10.0. Continuous data are presented as 
mean ± standard deviation (SD). Two-sided p-values ≤ 0.05 are considered statistically significant. Re-
admission and re-operation due to relapse incontinence was examined with the Kaplan-Meier analysis 
and log-rank test. The time analysis was measured in years, expressing the time period between the 
sling insertion and re-admission, resp. the second sling operation. No power analysis was performed 
due to the retrospective design. 
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Results 
520 (83%) of the 626 questionnaires sent were returned, of which 434/626 (69.1%) were completed  
IOQ questionnaires, 55 (8.8%) were returned by the post office (address not known in the electronic 
telephone directory and no addendum in the internal address system), 21 (3.4%) women had died, 6 
(1%) patients returned a blank IOQ, 4 questionnaires (0.6%) could not be properly evaluated because 
of serious cognitive disorders, and 108 (17.3%) were not returned by the patients. IVS and Reemex 
interventions were excluded from further evaluation, because of the small number of patients (<2% of 
all operations) and the different material of the sling. The following analysis included the 422 patients 
who had TVT, TOT or TVT-O. Among this group, patient compliance was good with a maximum of 
2.7% (1.3-5.7%) of missing data per item. 
The distribution of the slings during the observation period is shown in Figure 1. 278 of the 422 eligible 
patients had a preoperative urodynamic evaluation (65.9%). Table 1 shows the basic characteristics. 
With the exception of the lower age of the TVT group and the higher age in the TOT group, the three 
groups TVT, TOT, or TVT-O did not differ significantly in relation to preoperative basic characteristics 
such as body mass index, parity, history of smoking, hormone replacement therapy, and urodynamic 
parameters such as maximum urethral closure pressure, volume at first desire to void, and bladder 
capacity, where this data was available. Twenty-five patients had previous incontinence surgery, 
showing no statistically significant difference among the three groups (p=0.19, Fisher’s exact test). 
Concomitant prolapse surgery was performed in a total of 63 patients with clinical SUI (p=0.11, 
Fisher’s exact test).  
At the time of completion of the IOQ, the overall mean follow-up was 4.9±2.3 years. The mean follow-
up of the TVT group (5.5±2.4 years) was significantly longer than of the TOT (3.6±1.1 years) or TVT-O 
(2.9±1.0 years) group (p<0.001), due to the gradual introduction of these different sling techniques.  
The total impact of postoperative incontinence on QoL, as measured by means of VAS and IOQ 
scores, did not differ for the sling types, as shown in Table 2. With the exception of the IOQ5 score 
(feeling tired/drained/lacking energy) the subjective outcomes were comparable between the groups. 
The postoperative change in the sex life of the respondents shows a tendency in favour of the TVT 
and TVT-O sling, but is not statistically significant (p=0.056). 
The evaluation of question IOQ4 about re-admission revealed a total of 32 patients who underwent a 
second sling related operation (18 TVT (5.9%), 12 TOT (13.6%), 2 TVT-O (7.1%)). The percentage of 
patients without a second intervention after 1, 2, and 5 years is described as freedom from re-
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operation. Freedom from re-operation at 1, 2, and 5 years was 95.8±1.1%, 95.4±1.2% and 93.9±1.5% 
for TVT, 92.9±4.9% for TVT-O, and 93.1±2.7%, 88.3±3.5%, and 86.1±4.0% for TOT, respectively 
(p=0.029, log-rank test) (Fig. 2). Partial tape excision or resuturing of the vaginal wall due to tape 
erosion was performed in 10 patients (7 TVT (2.3%), 3 TOT (3.4%), no TVT-O). Complete tape 
incision was performed on 12 patients due to bladder outlet obstruction, recurrent urinary tract 
infections, or de-novo urge (10 TVT (3.3%), 1 TOT (1.1%), 1 TVT-O (3.6%)). Owing to relapse of 
stress urinary incontinence, 10 patients (1 TVT (0.3%), 8 TOT (9.0%), 1 TVT-O (3.6%)) received a 
second tape (9 TVT, 1 Remeex). One patient underwent an intravesical injection of Botulinumtoxin 
due to urge incontinence 15 months after insertion of a TOT and an antecedent tape incision. None of 
the patients with a repeat incontinence procedure had a prior incontinence surgery. Freedom from re-
operation for recurrent SUI at 1, 2, and 5 years was 100%, 99.7±0.3% and 99.7±0.3% for TVT, 100% 
for TVTO, and 94.3±2.5%, 91.8±3.0%, and 89.9±3.7% for TOT, respectively (p<0.001) (Fig. 3).
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Discussion 
In order to determine the efficacy of any treatment modality, the impact of the procedure on patient 
quality of life and long-term satisfaction must be evaluated and reported. This information needs to be 
provided in order for patients to make an accurately informed decision regarding their therapy. To the 
best of our knowledge, this is the first clinical application of the IOQ for assessing patient satisfaction 
in a clinical trial. An advantage of the IOQ is that it is applicable for post-treatment assessment of QOL 
following surgery for incontinence within the scope of clinical studies or as a quality control tool when 
preoperative questionnaires are not collected. 
 
The IOQ provides information on QoL, patient satisfaction, and complication rate in an accurate and 
comprehensive way after more than one year after operation. Up to now, no long-term data for 
acceptability, reliability and validity of the IOQ were available [14].  
Patient compliance was excellent as in the original publication, with less than 4 % missing data [14]. 
This was achieved in a study collective where 26.1% of patients were older than 70 years. 
Mean follow-up for TVT (5.4 years) was obviously longer than for TOT (3.5 years) and TVT-O (2.9 
years), as these were introduced subsequently in our clinic. 
Outcome parameters for QoL and subjective continence are similar for all three sling types, showing 
no time related decrease. This finding is corresponding with other studies providing subjective 
outcomes using validated questionnaires like the UDI-6 and IIQ-7, where the scores for retropubic and 
transobutrator slings were similar. Notably, retropubic slings were followed by significantly higher 
objective continence rates [15]. As short-term results of the TVT procedure are encouraging [16] and 
were supported by several authors [17,18], long-term results after sling insertion have been published 
in the last few years [7,19,11,12,13]. Like the Burch colposuspension, there seems to be a surgical 
success decline with TVT procedure after 5- and 7-year follow-up [20].  
Objectivelly we found an increased recurrence rate of incontinence in the TOT group leading to a 
significantly smaller freedom from re-operation. This might be a reason, why women with a TOT were 
the less satisfied with the preoperative information (IOQ16). The informed consent forms for all sling 
operations were the same and can be downloaded from the homepage of the Swiss Society of 
Obstetrics and Gynecology.  
Repeated procedures for incontinence are known to increase the risk of surgical failure after 
incontinence surgery [21,22]. Although it might be expected that recurrent incontinence could result 
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from previous incontinence surgery, none of our patients with a recurrence of SUI after sling 
procedure had had any prior incontinence surgery, and the preoperative MUCP did not differ among 
the groups [23]. There is a lack of data and guidelines for treatment of recurrent SUI and there is no 
clear guidance regarding the approach for secondary surgery which would offer the best result [24]. In 
our observational study, all secondary inserted slings were inserted by the retropubic route (11 TVT, 1 
Remeex). Recently, lower failure rates following retropubic slings have been published and there is 
some evidence to consider the insertion of a retropubic sling in the case of primary failure [25,26].  
There was no difference in the reporting of voiding difficulties (IOQ19) in our midterm follow-up, in 
contrast to a recent meta-analysis, where TOT and TVT-O caused less voiding difficulties [27]. 
However, the re-admission rate for sling release because of voiding difficulties (1day-45months after 
operation), as controlled by the clinical information system, was higher in the TVT group, but not yet 
statistically significant.   
Weaknesses of the study are the not uniform sample size with a majority of TVT, the varying length of 
follow-up, the differences in age and the inhomogeneous distribution of concomitant procedures due 
to the retrospective design of this study. Another flaw is the possible incorrect completion of questions 
like IOQ4 about re-admission (yes/no and the cause of the re-admission). To avoid misinterpretation, 
patient remarks about the reason for re-admission must be checked against a clinical information 
system. After cross-checking the patients answer with the clinical information system we state, that 
most patients reported the diagnosis of relapse incontinence correctly, whereas voiding difficulties 
resulting as a consequence of too tense slings, or tape erosions were reported by related symptoms 
such as urinary tract infection or incomplete bladder emptying. As the IOQ was designed for 
application 3 months after operation, some questions like IOQ5 [felt tired/drained/lacking] and IOQ6 
[felt irritable/snappy] are not appropriate questions in a follow-up longer than 3 months. The symptoms 
of fatigue and irritability are mostly dependent on a short date back operation or anesthesia.   
The slightly lower age in the TVT group is explained by a possible selection bias. In the early stage, 
we preferred the transobturator route for older patients, based on the rationale that this technique is 
less obstructive, while later the established retropubic route was preferred for younger and sexual 
active patients in order to avoid pain related sexual dysfunction caused by the TO passage [28,29].  
Most of the recurrent cases were in the TOT group. Except the older age of these patients, we do not 
have an explanation for this observation and can not exclude bias.   
The retrospective design of this study is a further weakness due to missing preoperative data such as 
the VAS for incontinence distress symptoms. The VAS for preoperative incontinence distress 
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symptoms was collected by the IOQ at time the questionnaire was completed, and this might be a 
recall bias and not represent the real discomfort the incontinence caused to the patient preoperatively. 
Nevertheless, the VAS has been proven to be a reliable and reproducible method for the assessment 
of quality of life in urogynecological research [30].  
The IOQ is categorized as a level C grade of recommendation by the 4th edition of the International 
Consultation on Incontinence, which implies that a questionnaire is in the early development stage and 
has future potential, but that further work is required and encouraged [9]. In our analysis, the IOQ 
proved to be a valuable and proper instrument to assess the subjective patient mid- to long-term 
outcome on various emotional, physical and social states, as well as on symptom distress data and 
readmission rate following sling surgery. Further studies are required to affirm our results. 
Conclusion 
Patient assessment using the IOQ showed that all sling procedures restore continence effectively with 
comparable mid-term outcome in relation to quality of life in women with stress urinary incontinence. In 
our survey, a higher postoperative incontinence rate was shown with TOT slings compared to TVT, 
and this occurred within a shorter observational interval. This raises the question whether TOT will 
maintain comparable long-term efficacy as TVT. 
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Figures and Figures legend 
 
Fig. 1 
Distribution of the sling types inserted during observation period 1999-2007 in the 422 eligible 
patients.  
 
 
 
Fig. 2  
Kaplan-Meier curve for re-operation depending on sling type. Log rank (Mantel Cox) test for equality of 
re-admission functions p=0.029. 
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Fig. 3  
Kaplan-Meier curve for second sling insertion due to relapse incontinence depending on sling type.  
Log rank test (Mantel Cox) for equality of relapse incontinence functions p=<0.001. 
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Table 1 
Table 1. Basic characteristics including preoperative urodynamic data of the 422 eligible patients. Data 
is expressed as mean±standard deviation (eligible patients in parenthesis), or number of patients 
(percentage). 
Pts, number of eligible patients 
* Kruskal-Wallis, ** Fisher’s exact test 
 TVT  
(pts.) 
TOT Monarc 
(pts.) 
TVTO 
(pts.) 
p-value 
N 306 (72.5%) 88 (20.9%) 28 (6.6%) - 
age at operation (years) 59.7±12.2 65.0±12.9 62.2±13.8 0.003* 
body mass index (kg/m2) 26.8±4.9 
(286) 
26.2±4.4 
(78) 
27.7±4.6 
(28) 
0.32* 
parity 2.5±1.1 
(277) 
2.6±1.3 
(76) 
2.5±1.0 
(22) 
0.85* 
history of smoking 103/300 
(34.2%) 
27/86 
(31.4%) 
5/27 
(18.5%) 
0.24* 
hormone replacement therapy 71/300(23.7%) 17/85(20.0%) 7/28(25.0%) 0.60* 
Urodynamic data     
maximum urethral closure pressure 
(cmH2O) 
43.3±23.3 
(203) 
38.6±19.1 
(45) 
51.7±26.9 
(19) 
0.18* 
volume at first desire to void (ml) 244.9±108.0 
(208) 
234.3±120.3 
(46) 
264.0±104.5 
(19) 
0.41* 
max. bladder capacity (ml) 452.9±104.8 
(208) 
424.4±128.4 
(48) 
479.1±108.7 
(20) 
0.21* 
preoperative post-void residual 
urine volume (ml) 
19.6±41.3 
(180) 
28.1±64.8 
(37) 
28.2±30.3 
(19) 
0.13* 
short-pad-test (g) 67.8±68.2 
(207) 
60.4±66.0 
(44) 
107.5±137.2 
(18) 
0.25* 
previous incontinence surgery 
 abdominal colposuspension 
 vaginal Colposuspension 
 sling insertion 
 botulinumtoxin intravesical 
 sling and botulinumtoxin 
 
11 
5 
0 
1 
0 
 
0 
0 
1 
0 
0 
 
3 
3 
0 
0 
1 
0.19** 
concomitant prolapse surgery 
 hysterectomy 
 colporrhaphia anterior 
 colporrhaphia posterior 
 sacrospinous ligament fixation 
 botulinumtoxin intravesical 
39 
19 
28 
23 
4 
1 
19 
9 
10 
11 
6 
3 
5 
2 
4 
2 
0 
1 
0.11* 
0.42** 
0.47** 
0.36** 
0.02** 
0.02** 
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Table 2 
Postoperative subjective long-term results. Data is expressed as mean±standard deviation (range). 
*Kruskal-Wallis test 
 
 TVT 
(306) 
TOT Monarc 
(88) 
TVTO 
(28) 
P value 
Follow-up (time interval between 
operation and completion of IOQ, 
in years) 
5.5±2.3 
(1.2 – 10.0) 
3.6±1.1 
(1.7 – 6.2) 
2.9±1.0 
(1.7 – 4.9) 
<0.001* 
VAS preoperative (0-10) 7.9±1.8 7.9±1.8 7.7±2.3 0.97* 
VAS postoperative (0-10) 2.4±2.6 2.1±2.9 2.3±2.9 0.21* 
Symptoms     
Pain (IOQ1) 9.9±21.9 7.5±15.3 8.9±16.0 0.97* 
Symptoms pre-operative (IOQ8) 76.7±23.4 75.0±24.0 71.4±28.6 0.65* 
Symptoms post-operative 
(IOQ9) 
18.1±26.7 22.1±30.4 15.2±25.8 0.51* 
OAB pre-operative (IOQ20) 74.4±43.7 80.0±40.2 85.2±36.2 0.30* 
Change in OAB symptoms pre- 
or post-operative (IOQ21) 
30.1±27.5 27.8±29.3 22.3±22.1 0.33* 
Complications     
Urinary infection (IOQ2) 37.4±48.5 29.9±46.0 33.3±48.0 0.42* 
Other infection (IOQ3) 19.1±39.4 12.9±33.8 21.4±41.8 0.38* 
Hospital re-admission (IOQ4) 7.1±25.7 14.8±35.7 7.1±26.2 0.08* 
Residual urine (IOQ19) 28.7±25.3 31.2±28.8 26.8±26.3 0.81* 
Quality of life     
Felt tired/drained/lacking (IOQ5) 42.2±28.3 41.2±28.0 23.2±25.4 0.003* 
Felt irritable/snappy (IOQ6) 38.1±28.0 34.1±24.7 28.6±31.7 0.13* 
Felt depressed/tearful (IOQ7) 38.1±29.9 36.6±27.0 35.7±35.6 0.83* 
Global evaluation of health 
(IOQ10) 
43.8±21.5 44.2±22.6 46.4±26.1 0.64* 
Limitations in daily activities 
(IOQ12) 
30.9±30.2 31.2±32.7 28.6±28.6 0.95* 
Change in sex life (IOQ13) 52.6±35.7 63.2±35.8 55.1±37.6 0.06* 
Change in feeling about body 
(IOQ14) 
25.3±30.2 27.9±33.1 23.2±28.8 0.82* 
Satisfaction     
Symptoms changes pre- and 
post-operative (IOQ11) 
14.1±25.5 17.7±30.2 17.9±30.3 0.73* 
Time of recovery (IOQ15) 33.7±30.6 38.8±37.2 32.1±33.9 0.67* 
Satisfaction with information 
(IOQ16) 
50.0±15.3 54.9±18.6 46.4±18.9 0.02* 
Improvement in well being 
(IOQ17) 
19.9±27.9 21.6±29.6 15.2±25.8 0.57* 
Recommending operation 
(IOQ18) 
15.2±29.6 19.4±32.1 14.3±30.7 0.35* 
IOQ QoL Score (0-100) 33.6±17.2 35.3±18.6 30.8±18.1 0.57* 
IOQ QoL extended Score (0-100) 31.9±16.9 33.7±18.9 27.9±17.9 0.35* 
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